InvestorsHub Logo
Followers 8
Posts 743
Boards Moderated 0
Alias Born 11/01/2006

Re: None

Wednesday, 10/01/2014 7:04:08 PM

Wednesday, October 01, 2014 7:04:08 PM

Post# of 335
Esperion Therapeutics announces positive top line phase 2b results for ETC-1002
4:25pm EDT

Oct 1 (Reuters) - Esperion Therapeutics :

* Esperion Therapeutics Announces Positive Top Line phase 2b results for ETC-1002

* Says ETC-1002-008 study meets primary endpoint; ETC-1002 appears to be safe and well tolerated

* Says ETC-1002 lowers LDL cholesterol significantly more than merck's zetia-study Source text for Eikon: Further company coverage:

Win a few. Lose a few.
Only the long term counts.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ESPR News